Arbutus Biopharma earnings date
Arbutus Biopharma (I9DN) Q3 2024 Earnings Report
DE:I9DN Q3 2024 EPS Results
- Actual EPS
- -EUR 0.09
- Consensus EPS
- -EUR 0.08
- Beat/Miss
- Missed by -EUR 0.01
- One Year Ago EPS
- -EUR 0.11
DE:I9DN Q3 2024 Revenue Results
- Actual Revenue
- EUR 1.20M
- Expected Revenue
- EUR 1.67M
- Beat/Miss
- Missed by -EUR 466.48K
- YoY Revenue Growth
- -71.25%
Earnings Announcement Details
- Quarter
- Q3 2024
- Date
- 11/06/2024
- Time
- Before Open
- Conference Call
- Wednesday, November 6, 2024
Arbutus Biopharma's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2024 Earnings Call Audio
Q3 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2024 Earnings Call Summary
The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.
In the third quarter 2024 earnings call for Arbutus Biopharma, the company provided several key metrics and updates on their ongoing efforts to develop a functional cure for chronic hepatitis B (HBV). They reported having approximately $131 million in cash and investments, with a projected cash burn for 2024 between $63 million and $67 million, ensuring their financial runway extends into the fourth quarter of 2026. The company is advancing their RNAi therapeutic imdusiran through Phase IIa trials, IM-PROVE I and II, which have shown promising results, such as a 33% surface antigen loss in Cohort A1 and 67% in patients with baseline antigen levels below 1,000 IU/mL. Moreover, they are progressing with their AB-101 clinical trial, with evidence of dose-dependent receptor occupancy in Phase Ia/Ib, and anticipate reporting preliminary HBV patient data in the first half of next year. The litigation with Moderna and Pfizer/BioNTech is ongoing, with a trial date set for September 2025 and a Markman hearing on December 18, 2024.
- Strong Financial PositionArbutus ended Q3 2024 with $131 million in cash, sufficient to fund operations into Q4 2026. A $44 million net proceeds from common shares issuance offset $54.5 million in operational cash usage.
- Promising Clinical Data for Hepatitis B TreatmentImdusiran showed promising results in reducing surface antigen levels in HBV patients. In Cohort A1 of the IM-PROVE I trial, 33% of patients achieved surface antigen loss sustained at 24 weeks post-treatment, with 67% of those with baseline less than 1,000 IU/mL maintaining loss.
- Upcoming Data PresentationsUpcoming presentations at the Liver Meeting 2024 and AASLD will showcase additional data from ongoing HBV trials, indicating continued progress and interest in Arbutus' research.
DE:I9DN Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | -0.02- | -0.01 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | -0.020.27 | -0.04 | 850.00% (+0.30) | |
| Aug 12, 2026 | 2026 (Q2) | -0.02-0.03 | 0.01 | -400.00% (-0.04) | |
| May 13, 2026 | 2026 (Q1) | -0.030.78 | -0.12 | 769.23% (+0.90) | |
| Mar 23, 2026 | 2025 (Q4) | -0.03-0.01 | -0.06 | 85.71% (+0.05) | |
| Nov 13, 2025 | 2025 (Q3) | -0.03-0.04 | -0.09 | 60.00% (+0.05) | |
| Aug 06, 2025 | 2025 (Q2) | -0.040.01 | -0.1 | 109.09% (+0.11) | |
| May 14, 2025 | 2025 (Q1) | -0.09-0.12 | -0.09 | -30.00% (-0.03) | |
| Mar 27, 2025 | 2024 (Q4) | -0.07-0.06 | -0.11 | 41.67% (+0.04) | |
| Nov 06, 2024 | 2024 (Q3) | -0.08-0.09 | -0.11 | 16.67% (+0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

